ABCG2 and colonic neoplasm: VKNG-1 has been identified as a novel ABCG2 inhibitor that has a favorable preclinical toxicity profile that can restore the in vitro and in vivo efficacy of chemotherapeutic drugs that are ABCG2 substrates in drug-resistant colon cancers (see Table 1 and Table 2).